Clinical Trial

Tapering of Inhaled Corticosteroids in Tezepelumab-treated Asthma patieNts: Impact on Clinical Outcomes

Study acronym: TITANIC
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
To evaluate the relationship between starting tezepelumab treatment followed by tapering of inhaled corticosteroid (ICS) and ICS dose, metabolic outcomes, asthma control and exacerbation rate in a real world setting
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-17.
Trial Details
NCT Number NCT07713498
Lead Sponsor Franciscus Gasthuis
Conditions Severe Asthma
Enrollment 61 participants
Start Date 2026-05-01
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-21